Targeting newly identified ERβ/TGFβ-1/SMAD3 signals with the FDA-approved antiestrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma

Published 2018 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Targeting newly identified ERβ/TGFβ-1/SMAD3 signals with the FDA-approved antiestrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-02
DOI
10.1002/1878-0261.12377

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.